MI Profile™ comprehensive profiling assesses DNA, RNA and Proteins from tumor tissue to reveal a more complete molecular blueprint that helps guide precise and individualized treatment decisions. Tests include next-generation sequencing (NGS), immunohistochemistry (IHC), chromogenic in situ hybridization (CISH), pyrosequencing, and AI-predictive algorithms for select tumor types.
- NGS: MI Cancer Seek™ (CDx) is performed when ordering MI Profile. If the sample does not meet specimen requirements, the order will reflex to MI Tumor Seek Hybrid™ (LDT).
- MI Cancer Seek (CDx)
- MI Tumor Seek Hybrid (LDT)
- IHC: 15+ tumor relevant protein biomarkers
- CISH: EBER (Gastric/GEJ and Head & Neck) and HPV (Head & Neck)
- Pyrosequencing: MGMT Methylation (Glioma)
- AI Signatures:Caris GPSai™ for CUP cases and Caris FOLFIRSTai™ for mCRC cases
SPECIMEN TYPE(S)
Tissue (FFPE)
Tissue (Fresh)
APPLICATION
Profiling for therapy selection